Detalhe da pesquisa
1.
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.
J Urol
; 199(2): 459-464, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28867562
2.
Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
Cancer
; 123(2): 253-262, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27648814
3.
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Cancer
; 123(12): 2303-2311, 2017 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28171710
4.
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
Prostate
; 75(8): 836-44, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25683285
5.
Increased survival with enzalutamide in prostate cancer after chemotherapy.
N Engl J Med
; 367(13): 1187-97, 2012 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-22894553
6.
Enzalutamide in European and North American men participating in the AFFIRM trial.
BJU Int
; 115(1): 41-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25123978
7.
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.
Lancet Oncol
; 15(10): 1147-56, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25104109
8.
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
Lancet Oncol
; 15(6): 592-600, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24739897
9.
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Lancet
; 375(9724): 1437-46, 2010 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-20398925
10.
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
Eur Urol
; 74(1): 37-45, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28844372
11.
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
J Clin Oncol
; 36(6): 572-580, 2018 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29272162
12.
Development of enzalutamide for metastatic castration-resistant prostate cancer.
Ann N Y Acad Sci
; 1358: 13-27, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26384731
13.
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
Eur Urol
; 67(2): 223-30, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25171902
14.
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
Eur Urol
; 68(5): 795-801, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25698064
15.
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
Eur Urol
; 68(5): 787-94, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25687533